Literature DB >> 31911011

Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?

Geraldine Pignot1, Antoine Thiery-Vuillemin2, Jochen Walz3, Hervé Lang4, Pierre Bigot5, Pierre Werle4, Loïc Balssa6, Lionnel Geoffrois7, Louis Leblanc8, Laurence Albigès9, Vincenzo di Nunno9, Karim Bensalah10, Sylvain Ladoire11, Gwenaelle Gravis12, Philippe Barthélémy13.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31911011     DOI： 10.1016/j.eururo.2019.12.018

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  11 in total

Review 1.  Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?

Authors:  Roser Vives Dilme; Juan Gómez Rivas; Riccardo Campi; Javier Puente; Tamara Jerez; Dmitry Enikeev; Francesco Esperto; Jesús Moreno Sierra
Journal:  Curr Urol Rep       Date:  2021-10-16       Impact factor: 3.092

Review 2.  Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.

Authors:  Alexandre Ingels; Riccardo Campi; Umberto Capitanio; Daniele Amparore; Riccardo Bertolo; Umberto Carbonara; Selcuk Erdem; Önder Kara; Tobias Klatte; Maximilian C Kriegmair; Michele Marchioni; Maria C Mir; Idir Ouzaïd; Nicola Pavan; Angela Pecoraro; Eduard Roussel; Alexandre de la Taille
Journal:  Nat Rev Urol       Date:  2022-05-11       Impact factor: 16.430

3.  Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.

Authors:  Maria I Carlo; Kyrollis Attalla; Yousef Mazaheri; Sounak Gupta; Onur Yildirim; Samuel J Murray; Devyn T Coskey; Ritesh Kotecha; Chung-Han Lee; Darren R Feldman; Paul Russo; Sujata Patil; Robert J Motzer; Jonathan A Coleman; Jeremy C Durack; Ying-Bei Chen; Oguz Akin; A Ari Hakimi; Martin H Voss
Journal:  Eur Urol       Date:  2022-02-17       Impact factor: 24.267

4.  Cytoreductive Nephrectomy in 2021: Obsolete but Necessary.

Authors:  Umberto Capitanio; Andrea Necchi; Francesco Montorsi; Alessandro Larcher
Journal:  Eur Urol Open Sci       Date:  2021-12-29

5.  Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation.

Authors:  Takanari Kambe; Toshinari Yamasaki; Yuta Mine; Hiroki Hagimoto; Hidetoshi Kokubun; Masashi Kubota; Naofumi Tsutsumi; Koji Inoue; Shigeo Hara; Mutsushi Kawakita
Journal:  IJU Case Rep       Date:  2022-03-25

Review 6.  The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.

Authors:  Hana Studentova; Nikol Rusarova; Andrea Ondruskova; Anezka Zemankova; Vladimir Student; Daniela Skanderova; Bohuslav Melichar
Journal:  Curr Oncol       Date:  2022-08-03       Impact factor: 3.109

Review 7.  Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature.

Authors:  Scott J Dawsey; Steven C Campbell; Moshe C Ornstein
Journal:  Curr Oncol       Date:  2021-05-20       Impact factor: 3.677

8.  Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.

Authors:  Michael A Gorin; Hiten D Patel; Steven P Rowe; Noah M Hahn; Hans J Hammers; Alice Pons; Bruce J Trock; Phillip M Pierorazio; Thomas R Nirschl; Daniela C Salles; Julie E Stein; Tamara L Lotan; Janis M Taube; Charles G Drake; Mohamad E Allaf
Journal:  Eur Urol Oncol       Date:  2021-05-26

9.  A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.

Authors:  Hana Studentova; Anezka Zemankova; Martina Spisarova; Daniela Skanderova; Zbynek Tudos; Bohuslav Melichar; Vladimir Student
Journal:  Medicina (Kaunas)       Date:  2022-02-23       Impact factor: 2.430

10.  Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b).

Authors:  Marco Stellato; Daniele Santini; Elena Verzoni; Ugo De Giorgi; Francesco Pantano; Chiara Casadei; Giuseppe Fornarini; Marco Maruzzo; Andrea Sbrana; Giuseppe Di Lorenzo; Mariella Soraru; Emanuele Naglieri; Sebastiano Buti; Rocco De Vivo; Andrea Napolitano; Francesca Vignani; Claudia Mucciarini; Francesco Grillone; Giandomenico Roviello; Marilena Di Napoli; Giuseppe Procopio
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.